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Alzheimer’s, Parkinson’s, Huntington’s, type II diabetes, and Mad Cow disease, or Cystic fi-
brosis, these apparently unrelated diseases, the so-called protein structural diseases, are found
to be a result of protein misfolding. Understanding the role of molecular inhibitors in formation
of amyloid fibrils plays an important role in finding proper treatments to those structural dis-
eases. In the case of Alzheimer’s disease, experiments showed that the fibrillation of full-length
Aβ peptides is disrupted by the peptide fragment Aβ16−20 (KLVFF). In this contribution,
we studied the kinetics of oligomerization of the system of two Aβ16−22 and one Aβ16−20
peptides, using all-atom simulations with the GROMOS96 force field 43a1 in explicit water.
In agreement with experiments, Aβ16−20 peptide was found to slow down the aggregation
process.
1 Introduction
In many cases protein aggregates take the form of amyloid fibrils, which appear as un-
branched rod-like nanostructures with the diameter of an order of 10 nm and varying
length1. A large body of evidence suggests that amyloid fibrils and associated oligomeric
intermediates are related to a number of diseases, including Alzheimer’s, Parkinson’s,
Huntington’s, and prion diseases1. For example, in the case of the Alzheimer’s disease
the memory decline may result from the accumulation of the amyloid β-proteins (Aβ)
present in two forms - 40 (Aβ1−40) and 42 (Aβ1−42) amino acids of which are produced
through endoproteolysis of the β-amyloid precursor transmembrane protein. Since struc-
tural diseases affect a significant portion of senior population, it is vital to develop ther-
apeutic approaches to combat the amyloid assembly. One of possible ways is to design
molecular inhibitors, which interfere with this process. For example, the peptide fragment
Aβ16−20 KLVFF2 and the peptide LPFFD derived from Aβ17−21 fragment by V18P and
A21D mutations3 can disrupt fibrillation of full-length Aβ peptide. An insertion of prolines
also inhibits amyloid formation. An another powerful strategy for inhibition is a peptide
N-methylation. It was demonstrated that themembrane-permeable NN-methylated pen-
tapeptide Aβ16− 20m is an effective fibrillogenesis inhibitor, capable of both preventing
fibril growth and disassembling existing fibrils4
In this contribution, we study the influence of a pentapeptide Aβ16−20 on the kinet-
ics of oligomerization of longer Aβ16−22 peptides, using all-atom simulations with the
GROMOS96 force field 43a1 in explicit water5. Since the fibril formation time tfibril
of a system of two Aβ16−22 and one Aβ16−20 peptide is much longer than that for three
Aβ16−22 peptides, one can expect that, in agreement with experiments2, Aβ16−20 fragment
slows down the fibril growth process.
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Figure 1. The free energy landscape as a function of V1 and V2. Typical conformations of some local minima
are shown.
2 Method and Results
The structures of monomeric Aβ16−20 and Aβ16−22 were extracted from the structure of
Aβ10−35 peptide available in the Protein Data Bank (ID: 1hz3). In order to study con-
formation changes of a monomer Aβ16−20, one trajectory of 150 ns was generated. The
initial configuration of the system of two Aβ16−22 and one Aβ16−20 was created by ran-
domly placing these peptides in a periodic box of volume 78 nm3 which corresponds to
the peptide concentration of 64 mM. For this system, four runs of 300, 343, 453, and 484
ns were carried out. All simulations were performed at T = 300 K.
We used the dihedral principal component analysis6 to compute the free energy land-
scapes (FEL), using the first two eigenvectors V1 and V2. In order to monitor the fibril
formation process, we use the ”liquid crystal” order parameter P2. If P ≥ 0.9 then the
system is considered to be in the fibril-like state6.
Fig. 1 shows the free energy of a monomer Aβ16−20 as a function of V1 and V2. The
existence of many shallow local minima separated by low barriers (of only a few kBT )
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Figure 2. Time dependence of P2 for the (2Aβ16−22+Aβ16−20) system. Shown is the structure at the largest
P2 ≈ 0.75. Interestingly, one Aβ16−22 and one Aβ16−20 adopt anti-parallel arrangement.
suggests that the system is not stable under thermal fluctuations. As evident from typi-
cal snapshots (Fig. 1), the monomer adopts mainly coil conformations. Comparing with
the free energy landscape of Aβ16−226, one can see that the pentapeptide Aβ16−20 is less
stable than Aβ16−22. This may be a reason why Aβ16−20 can serve as an inhibitor for
oligomerization of Aβ16−22 peptides, because in some situations proteins which have a
more ordered structure in the monomeric state, are expected to be more prone to aggrega-
tion.
The time dependence of the order parameter P2 for the (2Aβ16−22+Aβ16−20) system
is shown in Fig. 2. Since the largest value P2 ≈ 0.76, found at t ≈ 64 ns, is lower than
0.9, a fibril-like state does not occur in this run. This state was also not observed for three
other trajectories (results not shown). Therefore, for the (2Aβ16−22+Aβ16−20) system,
tfibril > 400 ns, which is larger than tfibril ≈ 200 ns for a system of three Aβ16−22
peptides6. This result suggests that, in agreement with the experiment2, Aβ16−20 can
interfere with the oligomerization process. There are two possible reasons for this:
(a) Aβ16−20 does not contain the negatively charged glutamic acid (E) as Aβ16−22 does.
(b) The replacement of Aβ16−22 by KLVFF reduces hydrophobicity of the whole system.
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In conclusion, we have shown that a short peptide KLVFF can inhibit the oligomer-
ization of a system of Aβ16−22 peptides. It is expected to prevent the fibril growth of
full-length Aβ peptides, due to charge imbalance.
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